Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose open-label TX000045 study in pulmonary hypertension with HFpEF
NL-OMON58992Phase 1Completed
- Sponsor
- Tectonic Therapeutic
- Start
- Jul 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Hormonal Peptides → Native Peptides → Peptides, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TX000045 in combined post-capillary and pre-capillary pulmonary hypertension, Isolated postcapillary pulmonary hypertension (Ipc-PH) and heart failure with preserved ejection fraction (HFpEF), sponsored by Tectonic Therapeutic. Started Jul 2024; status: completed.
02
Drugs
TX000045
03
Conditions
combined post-capillary and pre-capillary pulmonary hypertensionIsolated postcapillary pulmonary hypertension (Ipc-PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON58992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58992.